Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline

Arcturus Therapeutics ( (ARCT) ) has provided an announcement.

Arcturus Therapeutics named veteran biotech finance executive Dennis Mulroy as Chief Financial Officer effective May 1, 2026, with a compensation package including a $520,000 base salary, performance-based bonus eligibility and stock options vesting over four years, while interim finance chief Joe Roberts remains Controller and interim principal accounting officer. On May 7, 2026, the company reported first-quarter 2026 results showing a net loss of $27.0 million on sharply lower revenue and operating expenses as it pivots from COVID-19 vaccines toward rare disease programs, highlighted by earlier-than-expected Phase 2 enrollment for its inhaled cystic fibrosis therapy, regulatory progress and pediatric strategy for its ornithine transcarbamylase deficiency candidate, a strengthened C-suite, and a cash runway extending beyond the second quarter of 2028.

Arcturus initiated a 12-week open-label Phase 2 study of ARCT-032 in Class I cystic fibrosis patients in March 2026, monitoring lung function and quality-of-life metrics, and secured FDA guidance to advance its ARCT-810 ornithine transcarbamylase deficiency program toward a pivotal pediatric trial while partner Meiji prepares KOSTAIVE for Japan’s 2026/27 COVID-19 season. First-quarter 2026 research and development and general and administrative costs fell year over year due mainly to lower COVID-19 program and personnel expenses, reinforcing management’s claim of over two and a half years of funding capacity to reach key clinical and regulatory milestones across its rare disease portfolio.

Arcturus also bolstered its leadership bench with the appointment of Chief Medical Officer Alan H. Cohen, whose rare disease and pulmonology experience aligns with the company’s respiratory focus, and underscored Mulroy’s track record in SEC reporting and capital markets following his prior role at AnaptysBio. Management emphasized that the stronger balance sheet, refocused spending and ongoing collaborations with partners such as BARDA, CSL Seqirus and Meiji position the company to advance its mRNA platforms while reducing dependence on pandemic vaccine revenue.

The most recent analyst rating on (ARCT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.

Spark’s Take on ARCT Stock

According to Spark, TipRanks’ AI Analyst, ARCT is a Neutral.

The score is held back primarily by weak operating performance and negative free cash flow despite a strong, low-leverage balance sheet. Earnings-call updates add moderate support through regulatory/program milestones and an extended cash runway, while technicals are only modestly improved and valuation is constrained by a negative P/E and no dividend.

To see Spark’s full report on ARCT stock, click here.

More about Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., based in San Diego and listed on Nasdaq as ARCT, is a messenger RNA medicines company focused on liver and respiratory rare diseases. Its platform spans LUNAR lipid-mediated delivery, STARR self-amplifying mRNA and in-house mRNA manufacturing, supporting a pipeline that includes cystic fibrosis and ornithine transcarbamylase deficiency programs, as well as partnered COVID-19 and influenza vaccines, including the approved sa-mRNA COVID-19 vaccine KOSTAIVE.

Average Trading Volume: 449,346

Technical Sentiment Signal: Sell

Current Market Cap: $259.5M

Find detailed analytics on ARCT stock on TipRanks’ Stock Analysis page.